MK-0524B Lipid Study (MK-0524B-063)

PHASE3CompletedINTERVENTIONAL

Enrollment

2,414

Participants

Timeline

Start Date

June 15, 2007

Primary Completion Date

June 16, 2008

Study Completion Date

June 16, 2008

Conditions

Primary HypercholesterolemiaMixed Dyslipidemia

Interventions

DRUG

Comparator: simvastatin

DRUG

MK-0524A

Extended-release(ER) niacin/Laropiprant (MK-0524) Combination tablet

DRUG

Placebo

DRUG

MK-0524B

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00479882 - MK-0524B Lipid Study (MK-0524B-063) | Biotech Hunter | Biotech Hunter